materiaux

A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers. Led by Co-director Ralph Weichselbaum, investigator Wenbin Lin and postdoctoral researcher Kaiting Yang at the Ludwig Center at Chicago, the study describes the synthesis, mechanism of action and preclinical assessment of the nanoparticle, which is loaded with a drug that activates a protein central to the efficient induction of anti-cancer immunity.

It is vital for the procedure in-situ to be observed in many high vacuum and ultra-high vacuum (HV/UHV) processes. The challenge is that any optical component must penetrate the hermetically sealed chamber but not compromise the quality of the vacuum.